<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00826280</url>
  </required_header>
  <id_info>
    <org_study_id>3606-CL-3002</org_study_id>
    <nct_id>NCT00826280</nct_id>
  </id_info>
  <brief_title>Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)</brief_title>
  <official_title>A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Caffeine Intake on Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) in Subjects Administered Regadenoson</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observe whether the administration of caffeine prior to regadenoson will affect the
      interpretation of test results in subjects with coronary artery disease (CAD) undergoing
      SPECT MPI
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will undergo rest and stress scans. Those subjects who qualify by demonstrating
      at least 1 reversible defect, will undergo a third scan. All stress scans will involve the
      injection of regadenoson as the pharmacologic stress agent. Prior to the third scan, the
      subject will be administered blinded capsules of placebo or caffeine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 24, 2009</start_date>
  <completion_date type="Actual">July 15, 2010</completion_date>
  <primary_completion_date type="Actual">July 15, 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Number of Reversible Defects</measure>
    <time_frame>Day 3 and Day 5</time_frame>
    <description>Each segment of the 17-Segment Model was assessed for radiotracer uptake on a scale of 0 (normal uptake) to 4 (absent uptake). Segments were counted as having a reversible defect if the stress score was greater than the rest score and the stress score was ≥ 2.
Change was calculated as the number of reversible defects using regadenoson with caffeine/placebo (Day 5) minus the number of reversible defects using regadenoson alone (Day 3).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Summed Difference Score (SDS) Across All 17 Segments</measure>
    <time_frame>Day 3 and Day 5</time_frame>
    <description>The Summed Difference Score was calculated as the difference in the Summed Stress Score across the 17 segments (scan run under stress condition) minus the Summed Rest Score across the 17 segments (scan run under rest conditions).
Change in SDS was calculated as the SDS for regadenoson with caffeine/placebo stress scan (Day 5) minus the SDS for regadenoson only stress scan (Day 3).
The full range of the SDS is -68 to 68, where 0 represents no change between Summed Stress Score and Summed Rest Score. A higher positive score indicates more severe coronary artery disease (CAD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Reversible Defects Assessed by Computerized Quantitation</measure>
    <time_frame>Day 3 and Day 5</time_frame>
    <description>Each segment of the 17-Segment Model was assessed for radiotracer uptake on a scale of 0 (normal uptake) to 4 (absent uptake). Segments were counted as having a reversible defect if the stress score was greater than the rest score and the stress score was ≥ 2.
Change was calculated as the number of reversible defects using regadenoson with caffeine/placebo (Day 5) minus the number of reversible defects using regadenoson alone (Day 3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Summed Difference Score Across All 17 Segments Assessed by Computerized Quantitation</measure>
    <time_frame>Day 3 and Day 5</time_frame>
    <description>The Summed Difference Score was calculated as the difference in the Summed Stress Score across the 17 segments (scan run under stress condition) minus the Summed Rest Score across the 17 segments (scan run under rest conditions).
Change in SDS was calculated as the SDS for regadenoson with caffeine/placebo stress scan (Day 5) minus the SDS for regadenoson only stress scan (Day 3).
The full range of the SDS is -68 to 68, where 0 represents no change between Summed Stress Score and Summed Rest Score. A higher positive score indicates more severe coronary artery disease (CAD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart Rate</measure>
    <time_frame>Baseline, Day 5 (-3 min), Day 5 (+3 min), Day 5 (+15 min)</time_frame>
    <description>Baseline is the last non-missing measurement on or before first dose of regadenoson
Change is calculated as the time point minus baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure</measure>
    <time_frame>Baseline, Day 5 (-3 min), Day 5 (+3 min), Day 5 (+15 min)</time_frame>
    <description>Baseline is the last non-missing measurement on or before first dose of regadenoson.
Change is calculated as the time point minus baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure</measure>
    <time_frame>Baseline, Day 5 (-3 min), Day 5 (+3 min), Day 5 (+15 min)</time_frame>
    <description>Baseline is the last non-missing measurement on or before first dose of regadenoson.
Change is calculated as the time point minus baseline.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">347</enrollment>
  <condition>Coronary Artery Disease (CAD)</condition>
  <arm_group>
    <arm_group_label>Placebo plus Regadenoson</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two placebo capsules plus 0.4 mg regadenoson per 5mL intravenous (IV) bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caffeine 200 mg plus Regadenoson</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 200 mg Caffeine capsule and one placebo capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caffeine 400 mg plus Regadenoson</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 200 mg Caffeine capsules plus 0.4 mg regadenoson per 5mL intravenous bolus injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>regadenoson</intervention_name>
    <description>IV</description>
    <arm_group_label>Caffeine 400 mg plus Regadenoson</arm_group_label>
    <arm_group_label>Caffeine 200 mg plus Regadenoson</arm_group_label>
    <arm_group_label>Placebo plus Regadenoson</arm_group_label>
    <other_name>Lexiscan</other_name>
    <other_name>CVT 3146</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>overencapsulated caffeine</intervention_name>
    <description>oral</description>
    <arm_group_label>Caffeine 400 mg plus Regadenoson</arm_group_label>
    <arm_group_label>Caffeine 200 mg plus Regadenoson</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>technetium</intervention_name>
    <description>IV</description>
    <arm_group_label>Caffeine 400 mg plus Regadenoson</arm_group_label>
    <arm_group_label>Caffeine 200 mg plus Regadenoson</arm_group_label>
    <arm_group_label>Placebo plus Regadenoson</arm_group_label>
    <other_name>sestamibi</other_name>
    <other_name>tetrafosmin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>Placebo plus Regadenoson</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have undergone a previous diagnostic study [e.g., SPECT,
             echocardiography, magnetic resonance imaging (MRI), etc.] for a clinical indication
             demonstrating evidence of reversible defects in ≥ 1 vascular segment, have had other
             stress testing within the past 3 months, or the subject's history suggests at least a
             50% likelihood of CAD

               -  If the previous diagnostic study shows only 1 reversible defect and it is in
                  segment 17, another reversible defect will need to be present

          -  Subject with CAD must have an intermediate/low-risk for immediate intervention

          -  Subject must ingest caffeinated food or beverages regularly (at least the equivalent
             of one cup of caffeinated coffee daily)

          -  Subject must agree to not ingest any caffeine or other foods containing methylxanthine
             at least 24 hours prior to each study visit

          -  Subject must agree to abstain from eating solid food or drinking liquids other than
             water for at least 30 minutes prior to each study visit and 30 minutes following each
             study visit

        Exclusion Criteria:

          -  Subject with documented myocardial infarction (MI) ≤ 30 days prior to enrollment

          -  Subject with history of percutaneous coronary intervention (PCI) ≤ 4 weeks prior to
             enrollment

          -  Subject with history of coronary artery bypass graft (CABG) ≤ 8 weeks prior to
             enrollment

          -  Subject has prior history of heart transplantation

          -  Subject has unstable angina, known severe left main coronary artery stenosis, severe
             heart failure, uncontrolled arrhythmias, symptomatic hypotension or severe
             hypertension (systolic blood pressure &lt; 90 or &gt; 180 mmHg, respectively), or &gt; 1st
             degree atrioventricular block in the absence of a functioning pacemaker

          -  Subject requires emergent cardiac medical intervention or catheterization

          -  Subject has a history of smoking, regardless of frequency, tobacco type or method of
             intake, or using any smoking cessation products, including but not limited to the
             nicotine patch or nicotine gum, within 3 months prior to first dose of regadenoson

          -  Subject is currently undergoing treatment with theophylline, or theophylline
             containing medications within 7 days prior to randomization (Day 3)

          -  Subject has a history of known or suspected bronchoconstrictive or bronchospastic lung
             disease [e.g., asthma, wheezing, chronic obstructive pulmonary disease (COPD), etc.]

          -  Subject has a history of diabetes associated with gastric disorders and/or emptying

          -  Subject has end stage renal disease (ESRD) with a GFR&lt; 15mL/min or currently
             undergoing dialysis for ESRD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102-5037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsfield</city>
        <state>Massachusetts</state>
        <zip>01201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642-8679</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/study.aspx?ID=49</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2009</study_first_submitted>
  <study_first_submitted_qc>January 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2009</study_first_posted>
  <results_first_submitted>July 8, 2011</results_first_submitted>
  <results_first_submitted_qc>September 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 21, 2011</results_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacologic stress</keyword>
  <keyword>ischemia</keyword>
  <keyword>coronary artery disease (CAD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Regadenoson</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Plus Regadenoson</title>
          <description>Two Placebo capsules plus 0.4 mg regadenoson per 5mL intravenous (IV) bolus injection</description>
        </group>
        <group group_id="P2">
          <title>Caffeine 200 mg Plus Regadenoson</title>
          <description>One 200 mg Caffeine capsule and one placebo capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection</description>
        </group>
        <group group_id="P3">
          <title>Caffeine 400 mg Plus Regadenoson</title>
          <description>Two 200 mg Caffeine capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="116"/>
                <participants group_id="P3" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="113">Safety Analysis Set (SAF) was all randomized subjects who received at least one dose of regadenoson</participants>
                <participants group_id="P2" count="116">SAF was all randomized subjects who received at least one dose of regadenoson</participants>
                <participants group_id="P3" count="116">SAF was all randomized subjects who received at least one dose of regadenoson</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment</title>
              <participants_list>
                <participants group_id="P1" count="66">Subjects who completed treatment but had ≥ 1 non-interpretable scan were not included in FAS</participants>
                <participants group_id="P2" count="71">Subjects who completed treatment but had ≥ 1 non-interpretable scan were not included in FAS</participants>
                <participants group_id="P3" count="72">Subjects who completed treatment but had ≥ 1 non-interpretable scan were not included in FAS</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66">Ending Population equals FAS, all randomized subjects with interpretable MPI scans</participants>
                <participants group_id="P2" count="70">Ending Population equals FAS, all randomized subjects with interpretable MPI scans</participants>
                <participants group_id="P3" count="71">Ending Population equals FAS, all randomized subjects with interpretable MPI scans</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized but drug not received</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor discontinued subject or study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reversible ischemic defect not present</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Interpretation Failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Machine Failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>One or more non-interpretable scan</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Plus Regadenoson</title>
          <description>Two Placebo capsules plus 0.4 mg regadenoson per 5mL intravenous (IV) bolus injection</description>
        </group>
        <group group_id="B2">
          <title>Caffeine 200 mg Plus Regadenoson</title>
          <description>One 200 mg Caffeine capsule and one placebo capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection</description>
        </group>
        <group group_id="B3">
          <title>Caffeine 400 mg Plus Regadenoson</title>
          <description>Two 200 mg Caffeine capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="71"/>
            <count group_id="B4" value="207"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.0" spread="9.99"/>
                    <measurement group_id="B2" value="65.7" spread="11.11"/>
                    <measurement group_id="B3" value="69.4" spread="8.23"/>
                    <measurement group_id="B4" value="67.7" spread="9.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Number of Reversible Defects</title>
        <description>Each segment of the 17-Segment Model was assessed for radiotracer uptake on a scale of 0 (normal uptake) to 4 (absent uptake). Segments were counted as having a reversible defect if the stress score was greater than the rest score and the stress score was ≥ 2.
Change was calculated as the number of reversible defects using regadenoson with caffeine/placebo (Day 5) minus the number of reversible defects using regadenoson alone (Day 3).</description>
        <time_frame>Day 3 and Day 5</time_frame>
        <population>The number of participants analyzed represents Full Analysis Set (FAS), which included all randomized subjects with interpretable Myocardial Perfusion Imaging (MPI) scans.
The number of participants per arm is consistent for all categories of the data table.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Regadenoson</title>
            <description>Two Placebo capsules plus 0.4 mg regadenoson per 5mL intravenous (IV) bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Caffeine 200 mg Plus Regadenoson</title>
            <description>One 200 mg Caffeine capsule and one placebo capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Caffeine 400 mg Plus Regadenoson</title>
            <description>Two 200 mg Caffeine capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Reversible Defects</title>
          <description>Each segment of the 17-Segment Model was assessed for radiotracer uptake on a scale of 0 (normal uptake) to 4 (absent uptake). Segments were counted as having a reversible defect if the stress score was greater than the rest score and the stress score was ≥ 2.
Change was calculated as the number of reversible defects using regadenoson with caffeine/placebo (Day 5) minus the number of reversible defects using regadenoson alone (Day 3).</description>
          <population>The number of participants analyzed represents Full Analysis Set (FAS), which included all randomized subjects with interpretable Myocardial Perfusion Imaging (MPI) scans.
The number of participants per arm is consistent for all categories of the data table.</population>
          <units>Reversible Defects</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Stress Scan (Day 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="1.377"/>
                    <measurement group_id="O2" value="1.01" spread="1.452"/>
                    <measurement group_id="O3" value="1.00" spread="1.595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Double-Blind Stress Scan (Day 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="1.511"/>
                    <measurement group_id="O2" value="0.40" spread="0.907"/>
                    <measurement group_id="O3" value="0.38" spread="0.962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DoubleBlind - Baseline (Day 5 - Day 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.981"/>
                    <measurement group_id="O2" value="-0.61" spread="1.097"/>
                    <measurement group_id="O3" value="-0.62" spread="1.367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-Value applies to 'Double-Blind - Baseline (Day 5 - Day 3)'.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-Value is from the primary analysis using ANCOVA.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-Value applies to 'Double-Blind - Baseline (Day 5 - Day 3)'.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The unadjusted P-Values for pairwise differences should be used for interpretation only if the treatment effect's P-Value ≤ 0.05.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-Value applies to 'Double-Blind - Baseline (Day 5 - Day 3)'.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The unadjusted P-Values for pairwise differences should be used for interpretation only if the treatment effect's P-Value ≤ 0.05.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-Value applies to 'Double-Blind - Baseline (Day 5 - Day 3)'.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9328</p_value>
            <p_value_desc>The unadjusted P-Values for pairwise differences should be used for interpretation only if the treatment effect's P-Value ≤ 0.05.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Summed Difference Score (SDS) Across All 17 Segments</title>
        <description>The Summed Difference Score was calculated as the difference in the Summed Stress Score across the 17 segments (scan run under stress condition) minus the Summed Rest Score across the 17 segments (scan run under rest conditions).
Change in SDS was calculated as the SDS for regadenoson with caffeine/placebo stress scan (Day 5) minus the SDS for regadenoson only stress scan (Day 3).
The full range of the SDS is -68 to 68, where 0 represents no change between Summed Stress Score and Summed Rest Score. A higher positive score indicates more severe coronary artery disease (CAD).</description>
        <time_frame>Day 3 and Day 5</time_frame>
        <population>The number of participants analyzed represents Full Analysis Set (FAS), which included all randomized subjects with interpretable MPI scans.
The number of participants per arm is consistent for all categories of the data table.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Regadenoson</title>
            <description>Two Placebo capsules plus 0.4 mg regadenoson per 5mL intravenous (IV) bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Caffeine 200 mg Plus Regadenoson</title>
            <description>One 200 mg Caffeine capsule and one placebo capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Caffeine 400 mg Plus Regadenoson</title>
            <description>Two 200 mg Caffeine capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Summed Difference Score (SDS) Across All 17 Segments</title>
          <description>The Summed Difference Score was calculated as the difference in the Summed Stress Score across the 17 segments (scan run under stress condition) minus the Summed Rest Score across the 17 segments (scan run under rest conditions).
Change in SDS was calculated as the SDS for regadenoson with caffeine/placebo stress scan (Day 5) minus the SDS for regadenoson only stress scan (Day 3).
The full range of the SDS is -68 to 68, where 0 represents no change between Summed Stress Score and Summed Rest Score. A higher positive score indicates more severe coronary artery disease (CAD).</description>
          <population>The number of participants analyzed represents Full Analysis Set (FAS), which included all randomized subjects with interpretable MPI scans.
The number of participants per arm is consistent for all categories of the data table.</population>
          <units>Sum Difference Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Stress Scan (Day 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" spread="3.013"/>
                    <measurement group_id="O2" value="2.45" spread="2.909"/>
                    <measurement group_id="O3" value="2.53" spread="3.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Double-Blind Stress Scan (Day 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" spread="3.247"/>
                    <measurement group_id="O2" value="1.42" spread="2.091"/>
                    <measurement group_id="O3" value="1.27" spread="2.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DoubleBlind - Baseline (Day 5 - Day 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="2.871"/>
                    <measurement group_id="O2" value="-1.03" spread="2.071"/>
                    <measurement group_id="O3" value="-1.25" spread="2.664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-Value applies to 'Double-Blind - Baseline (Day 5 - Day 3)'.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <p_value_desc>P-Value is from the primary analysis using ANCOVA.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-Value applies to 'Double-Blind - Baseline (Day 5 - Day 3)'.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0034</p_value>
            <p_value_desc>The unadjusted P-Values for pairwise differences should be used for interpretation only if the treatment effect's P-Value ≤ 0.05.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-Value applies to 'Double-Blind - Baseline (Day 5 - Day 3)'.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The unadjusted P-Values for pairwise differences should be used for interpretation only if the treatment effect's P-Value ≤ 0.05.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-Value applies to 'Double-Blind - Baseline (Day 5 - Day 3)'.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5902</p_value>
            <p_value_desc>The unadjusted P-Values for pairwise differences should be used for interpretation only if the treatment effect's P-Value ≤ 0.05.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Reversible Defects Assessed by Computerized Quantitation</title>
        <description>Each segment of the 17-Segment Model was assessed for radiotracer uptake on a scale of 0 (normal uptake) to 4 (absent uptake). Segments were counted as having a reversible defect if the stress score was greater than the rest score and the stress score was ≥ 2.
Change was calculated as the number of reversible defects using regadenoson with caffeine/placebo (Day 5) minus the number of reversible defects using regadenoson alone (Day 3).</description>
        <time_frame>Day 3 and Day 5</time_frame>
        <population>The number of participants analyzed per arm represents Full Analysis Set (FAS), all randomized subjects with interpretable MPI scans. The number of participants included in the calculation for each visit is noted in the category titles, as “N”.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Regadenoson</title>
            <description>Two Placebo capsules plus 0.4 mg regadenoson per 5mL intravenous (IV) bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Caffeine 200 mg Plus Regadenoson</title>
            <description>One 200 mg Caffeine capsule and one placebo capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Caffeine 400 mg Plus Regadenoson</title>
            <description>Two 200 mg Caffeine capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Reversible Defects Assessed by Computerized Quantitation</title>
          <description>Each segment of the 17-Segment Model was assessed for radiotracer uptake on a scale of 0 (normal uptake) to 4 (absent uptake). Segments were counted as having a reversible defect if the stress score was greater than the rest score and the stress score was ≥ 2.
Change was calculated as the number of reversible defects using regadenoson with caffeine/placebo (Day 5) minus the number of reversible defects using regadenoson alone (Day 3).</description>
          <population>The number of participants analyzed per arm represents Full Analysis Set (FAS), all randomized subjects with interpretable MPI scans. The number of participants included in the calculation for each visit is noted in the category titles, as “N”.</population>
          <units>Reversible Defects</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Stress Scan (Day 3) [N=64; 69; 70]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="1.927"/>
                    <measurement group_id="O2" value="2.00" spread="2.364"/>
                    <measurement group_id="O3" value="2.19" spread="2.122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Double-Blind Stress Scan (Day 5) [N=66; 70; 71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="2.355"/>
                    <measurement group_id="O2" value="1.46" spread="1.954"/>
                    <measurement group_id="O3" value="1.42" spread="1.794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DoubleBlind - Baseline (Day 5-Day 3)[N=64; 69; 70]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="1.622"/>
                    <measurement group_id="O2" value="-0.59" spread="1.743"/>
                    <measurement group_id="O3" value="-0.81" spread="1.812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-Value applies to 'Double-Blind - Baseline (Day 5 - Day 3)'.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0037</p_value>
            <p_value_desc>P-Value is from the primary analysis using ANCOVA.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-Value applies to 'Double-Blind - Baseline (Day 5 - Day 3)'.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0089</p_value>
            <p_value_desc>The unadjusted P-Values for pairwise differences should be used for interpretation only if the treatment effect's P-Value ≤ 0.05.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-Value applies to 'Double-Blind - Baseline (Day 5 - Day 3)'.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0016</p_value>
            <p_value_desc>The unadjusted P-Values for pairwise differences should be used for interpretation only if the treatment effect's P-Value ≤ 0.05.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-Value applies to 'Double-Blind - Baseline (Day 5 - Day 3)'.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5654</p_value>
            <p_value_desc>The unadjusted P-Values for pairwise differences should be used for interpretation only if the treatment effect's P-Value ≤ 0.05.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Summed Difference Score Across All 17 Segments Assessed by Computerized Quantitation</title>
        <description>The Summed Difference Score was calculated as the difference in the Summed Stress Score across the 17 segments (scan run under stress condition) minus the Summed Rest Score across the 17 segments (scan run under rest conditions).
Change in SDS was calculated as the SDS for regadenoson with caffeine/placebo stress scan (Day 5) minus the SDS for regadenoson only stress scan (Day 3).
The full range of the SDS is -68 to 68, where 0 represents no change between Summed Stress Score and Summed Rest Score. A higher positive score indicates more severe coronary artery disease (CAD).</description>
        <time_frame>Day 3 and Day 5</time_frame>
        <population>The number of participants analyzed per arm represents Full Analysis Set (FAS), all randomized subjects with interpretable MPI scans. The number of participants included in the calculation for each visit is noted in the category titles, as “N”.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Regadenoson</title>
            <description>Two Placebo capsules plus 0.4 mg regadenoson per 5mL intravenous (IV) bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Caffeine 200 mg Plus Regadenoson</title>
            <description>One 200 mg Caffeine capsule and one placebo capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Caffeine 400 mg Plus Regadenoson</title>
            <description>Two 200 mg Caffeine capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Summed Difference Score Across All 17 Segments Assessed by Computerized Quantitation</title>
          <description>The Summed Difference Score was calculated as the difference in the Summed Stress Score across the 17 segments (scan run under stress condition) minus the Summed Rest Score across the 17 segments (scan run under rest conditions).
Change in SDS was calculated as the SDS for regadenoson with caffeine/placebo stress scan (Day 5) minus the SDS for regadenoson only stress scan (Day 3).
The full range of the SDS is -68 to 68, where 0 represents no change between Summed Stress Score and Summed Rest Score. A higher positive score indicates more severe coronary artery disease (CAD).</description>
          <population>The number of participants analyzed per arm represents Full Analysis Set (FAS), all randomized subjects with interpretable MPI scans. The number of participants included in the calculation for each visit is noted in the category titles, as “N”.</population>
          <units>Summed Difference Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Stress Scan (Day 3) [N=64; 69; 70]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" spread="4.383"/>
                    <measurement group_id="O2" value="4.46" spread="4.604"/>
                    <measurement group_id="O3" value="4.29" spread="4.314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Double-Blind Stress Scan (Day 5) [N=66; 70; 71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.41" spread="4.874"/>
                    <measurement group_id="O2" value="3.10" spread="4.737"/>
                    <measurement group_id="O3" value="2.46" spread="3.601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DoubleBlind - Baseline (Day 5-Day 3)[N=64; 69; 70]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="3.364"/>
                    <measurement group_id="O2" value="-1.45" spread="3.890"/>
                    <measurement group_id="O3" value="-1.84" spread="3.658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-Value applies to 'Double-Blind - Baseline (Day 5 - Day 3)'.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-Value is from the primary analysis using ANCOVA.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-Value applies to 'Double-Blind - Baseline (Day 5 - Day 3)'.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The unadjusted P-Values for pairwise differences should be used for interpretation only if the treatment effect's P-Value ≤ 0.05.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-Value applies to 'Double-Blind - Baseline (Day 5 - Day 3)'.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The unadjusted P-Values for pairwise differences should be used for interpretation only if the treatment effect's P-Value ≤ 0.05.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>P-Value applies to 'Double-Blind - Baseline (Day 5 - Day 3)'.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.4246</p_value>
            <p_value_desc>The unadjusted P-Values for pairwise differences should be used for interpretation only if the treatment effect's P-Value ≤ 0.05.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Heart Rate</title>
        <description>Baseline is the last non-missing measurement on or before first dose of regadenoson
Change is calculated as the time point minus baseline.</description>
        <time_frame>Baseline, Day 5 (-3 min), Day 5 (+3 min), Day 5 (+15 min)</time_frame>
        <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) all randomized patients who received at least one dose of regadenoson. The number of participants included in the calculation for each visit is noted in the category titles, as “N”.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Regadenoson</title>
            <description>Two Placebo capsules plus 0.4 mg regadenoson per 5mL intravenous (IV) bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Caffeine 200 mg Plus Regadenoson</title>
            <description>One 200 mg Caffeine capsule and one placebo capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Caffeine 400 mg Plus Regadenoson</title>
            <description>Two 200 mg Caffeine capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate</title>
          <description>Baseline is the last non-missing measurement on or before first dose of regadenoson
Change is calculated as the time point minus baseline.</description>
          <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) all randomized patients who received at least one dose of regadenoson. The number of participants included in the calculation for each visit is noted in the category titles, as “N”.</population>
          <units>Beats per minute</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [N=113; 116; 116]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0" lower_limit="46" upper_limit="96"/>
                    <measurement group_id="O2" value="62.0" lower_limit="45" upper_limit="92"/>
                    <measurement group_id="O3" value="64.0" lower_limit="47" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 5 (- 3 min) [N=67; 70; 71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-23" upper_limit="51"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-29" upper_limit="75"/>
                    <measurement group_id="O3" value="-2.0" lower_limit="-22" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 5 (+3 min) [N=67; 70; 72]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="-20" upper_limit="38"/>
                    <measurement group_id="O2" value="5.0" lower_limit="-23" upper_limit="58"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-16" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 5 (+15 min) [N=66; 72; 72]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="-19" upper_limit="31"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-21" upper_limit="63"/>
                    <measurement group_id="O3" value="-1.0" lower_limit="-20" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure</title>
        <description>Baseline is the last non-missing measurement on or before first dose of regadenoson.
Change is calculated as the time point minus baseline.</description>
        <time_frame>Baseline, Day 5 (-3 min), Day 5 (+3 min), Day 5 (+15 min)</time_frame>
        <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) all randomized patients who received at least one dose of regadenoson. The number of participants included in the calculation for each visit is noted in the category titles, as “N”.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Regadenoson</title>
            <description>Two Placebo capsules plus 0.4 mg regadenoson per 5mL intravenous (IV) bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Caffeine 200 mg Plus Regadenoson</title>
            <description>One 200 mg Caffeine capsule and one placebo capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Caffeine 400 mg Plus Regadenoson</title>
            <description>Two 200 mg Caffeine capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure</title>
          <description>Baseline is the last non-missing measurement on or before first dose of regadenoson.
Change is calculated as the time point minus baseline.</description>
          <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) all randomized patients who received at least one dose of regadenoson. The number of participants included in the calculation for each visit is noted in the category titles, as “N”.</population>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [N=113; 116; 116]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.0" lower_limit="95" upper_limit="184"/>
                    <measurement group_id="O2" value="131.0" lower_limit="88" upper_limit="180"/>
                    <measurement group_id="O3" value="135.0" lower_limit="100" upper_limit="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 5 (- 3 min) [N=67;70;71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-26" upper_limit="46"/>
                    <measurement group_id="O2" value="12.0" lower_limit="-35" upper_limit="58"/>
                    <measurement group_id="O3" value="11.0" lower_limit="-20" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 5 (+3 min) [N=67; 70; 72]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-37" upper_limit="36"/>
                    <measurement group_id="O2" value="8.0" lower_limit="-42" upper_limit="52"/>
                    <measurement group_id="O3" value="7.5" lower_limit="-25" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 5 (+15 min) [N=66; 72; 72]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-37" upper_limit="37"/>
                    <measurement group_id="O2" value="8.0" lower_limit="-30" upper_limit="68"/>
                    <measurement group_id="O3" value="5.0" lower_limit="-26" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure</title>
        <description>Baseline is the last non-missing measurement on or before first dose of regadenoson.
Change is calculated as the time point minus baseline.</description>
        <time_frame>Baseline, Day 5 (-3 min), Day 5 (+3 min), Day 5 (+15 min)</time_frame>
        <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) all randomized patients who received at least one dose of regadenoson. The number of participants included in the calculation for each visit is noted in the category titles, as “N”.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus Regadenoson</title>
            <description>Two Placebo capsules plus 0.4 mg regadenoson per 5mL intravenous (IV) bolus injection</description>
          </group>
          <group group_id="O2">
            <title>Caffeine 200 mg Plus Regadenoson</title>
            <description>One 200 mg Caffeine capsule and one placebo capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection</description>
          </group>
          <group group_id="O3">
            <title>Caffeine 400 mg Plus Regadenoson</title>
            <description>Two 200 mg Caffeine capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure</title>
          <description>Baseline is the last non-missing measurement on or before first dose of regadenoson.
Change is calculated as the time point minus baseline.</description>
          <population>The number of participants analyzed per arm represents Safety Analysis Set (SAF) all randomized patients who received at least one dose of regadenoson. The number of participants included in the calculation for each visit is noted in the category titles, as “N”.</population>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [N= 113; 116;116]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0" lower_limit="45" upper_limit="100"/>
                    <measurement group_id="O2" value="74.0" lower_limit="48" upper_limit="102"/>
                    <measurement group_id="O3" value="73.0" lower_limit="51" upper_limit="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 5 (- 3 min) [N=67; 70; 71]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-22" upper_limit="14"/>
                    <measurement group_id="O2" value="4.0" lower_limit="-19" upper_limit="20"/>
                    <measurement group_id="O3" value="6.0" lower_limit="-12" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 5 (+ 3 min) [N=67; 70; 72]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-19" upper_limit="23"/>
                    <measurement group_id="O2" value="4.0" lower_limit="-20" upper_limit="30"/>
                    <measurement group_id="O3" value="3.0" lower_limit="-22" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 5 (+15 min) [N=66; 72; 72]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-26" upper_limit="18"/>
                    <measurement group_id="O2" value="3.0" lower_limit="-18" upper_limit="23"/>
                    <measurement group_id="O3" value="4.0" lower_limit="-16" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Beginning of Day 3 through the Day 6 visit. All Serious Adverse Events occurring until 30 days after dosing were to be reported.</time_frame>
      <desc>Any untoward medical occurrence that occurred at the beginning of day 3 (Baseline Stress Scan) through the day 6 visit (considered &quot;treatment- emergent&quot;) was recorded as an Adverse Event.
Within a system organ class subjects may have reported more than one type of Adverse Event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Plus Regadenoson</title>
          <description>Two Placebo capsules plus 0.4 mg regadenoson per 5mL intravenous (IV) bolus injection</description>
        </group>
        <group group_id="E2">
          <title>Caffeine 200 mg Plus Regadenoson</title>
          <description>One 200 mg Caffeine capsule and one placebo capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection</description>
        </group>
        <group group_id="E3">
          <title>Caffeine 400 mg Plus Regadenoson</title>
          <description>Two 200 mg Caffeine capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Myocardial infraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Acute myocardial infraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site’s manuscript at least 30 days prior to publication to ensure that no confidential information of Sponsor is included in the document. Sponsor may delay the publication for an additional 60 days to seek patent protection.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Medical Director</name_or_title>
      <organization>Astellas Pharma Global Development</organization>
      <email>clinicaltrials@us.astellas.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

